ABSTRACT:The gut hormone peptide YY 3-36 ] has been suggested to posses anorexigenic actions in animals and human adults. However, its circulating concentrations and function have not been studied in neonates. Serum concentrations of PYY (3-36) were determined by RIA (RIA) in 62 healthy preterm infants [mean(SD) gestational age, 32.0(2.1) weeks; postnatal age, 40.9(14.8 d)] and 15 healthy fullterm infants of comparable postnatal age and gender. The correlations between PYY (3-36) levels and anthropometric characteristics, food intake, growth rates and circulating concentrations of total PYY, ghrelin, leptin, insulin and adiponectin were examined. Mean (SD) PYY (3-36) concentrations were higher in preterm [543.7(157.6) ng/L) than full term infants [350.9(114.1) ng/L; p Ͻ 0.001) and accounted for 48% and 42% of total PYY basal plasma immunoreactivity in preterm and full term infants, respectively. In multiple regression analysis, concentrations correlated negatively with the infants' BMI and positively with serum ghrelin concentrations, but not with caloric intake, weight gain or concentrations of any other hormone studied. In conclusion, PYY (3-36) represents almost half of total PYY immunoreactivity in neonates. It's correlations with ghrelin and BMI suggest a role of this peptide in the regulation of energy homeostasis; however, its specific functions and physiologic significance in neonates remain to be elucidated. ] is one of the two major molecular forms of the gut peptide YY, the other isoform being PYY (1-36) (1). Both isoforms, in addition to exerting secretory and motor activities throughout the gut (2,3), are involved in the central regulation of food intake and energy balance. Both peptides have an anorexigenic effect through a Y2 receptor-mediated mechanism at the level of hypothalamus, whereas PYY (1-36) also possesses orexigenic action by acting at central Y1 receptors (3,4). PYY (3-36) is more potent than PYY (1-36) in several effects, such as decrease of food intake and inhibition of gastric emptying (3).In adults, PYY (3-36) accounts for 37% and 54% of total PYY immunoreactivity in basal and postprandial plasma, respectively (1). However, circulating levels of PYY (3-36)have not been measured in neonates so far. The aim of the present study was to determine the circulating concentrations of PYY (3-36) in preterm and full term infants and to examine their possible associations with the infants' size, caloric intake, weight gain and the serum concentrations of total PYY or other hormones implicated in the regulation of metabolism, such as ghrelin, leptin, insulin and adiponectin (5,6).
METHODSStudy population and protocol. Sixty-two preterm [mean (SD) gestational age, 32.0 (2.1) weeks; birth weight, 1542 (275) g; males, 28] and 15 healthy full term infants [gestational age, 39.0 (1.0) weeks; birth weight, 3200 (498) g; males, 6] who served as the reference group were studied. Full term infants had similar gender distribution to that of preterm infants. Gestational age was estimated from the last ...